Research graph
References from Normal-immunopeptidome denominator: a safety atlas for immunotherapies targeting non-canonical and aberrantly expressed tumor antigens. Local targets link to admitted publications; unresolved targets remain external evidence.
Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer
10.1038/s43018-025-00979-2 · 2025 · External reference
10.1038/s41571-020-0387-x
10.1038/s41571-020-0387-x · External reference
10.1182/blood-2013-03-490565
10.1182/blood-2013-03-490565 · External reference
10.1097/cji.0b013e3182829903
10.1097/cji.0b013e3182829903 · External reference
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
10.1136/jitc-2020-002071 · 2021 · External reference
PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
10.1136/jitc-2024-011366 · 2025 · External reference
10.1093/nar/gkac776
10.1093/nar/gkac776 · External reference
Deciphering the MHC immunopeptidome of human cancers with Ligand.MHC atlas
10.1093/bib/bbaf314 · 2025 · External reference
HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry
10.1136/jitc-2025-012083 · 2025 · External reference
A systematic safety pipeline for selection of T-cell receptors to enter clinical use
10.1038/s41541-023-00713-y · 2023 · External reference
